A Multicenter, Controlled, Open-Label Extension (OLE) Study To Assess the Long-Term Safety and Efficacy of Evolocumab (AMG 145)

Trial Profile

A Multicenter, Controlled, Open-Label Extension (OLE) Study To Assess the Long-Term Safety and Efficacy of Evolocumab (AMG 145)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Evolocumab (Primary)
  • Indications Hypercholesterolaemia
  • Focus Adverse reactions
  • Acronyms OSLER; OSLER-1; PROFICIO
  • Sponsors Amgen
  • Most Recent Events

    • 31 Jul 2017 Results of a pooled analysis assessing the effect of evolocumab therapy over 1 year in 2 open-label extension studies (OSLER-1 and OSLER-2; n=4802) published in the American Journal of Cardiology
    • 18 Jul 2017 This trial has been completed in Czech Republic, as per European Clinical Trials Database record.
    • 04 Jul 2017 This trial has been completed in Spain as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top